Sign In
Buy OPNT
$20.65
+0 (+0%)
At Close: May 26, 2023
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Expected to Announce Quarterly Sales of $14.38 Million
07:14pm, Friday, 19'th Nov 2021 Dakota Financial News
Wall Street brokerages expect that Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will post $14.38 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Opiant Pharmaceuticals earnings. The highest sales estimate is $14.60 million and the lowest is $14.15 million. Opiant Pharmaceuticals reported sales of $9.92 million in the []
Brokerages Expect Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) to Announce -$0.25 EPS
12:20pm, Sunday, 14'th Nov 2021 Transcript Daily
Analysts expect Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) to post ($0.25) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Opiant Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.23) and the lowest estimate coming in at ($0.27). Opiant Pharmaceuticals posted earnings per share of ($0.16) during the []
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2021 Results - Earnings Call Transcript
08:00pm, Thursday, 11'th Nov 2021
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2021 Results - Earnings Call Transcript
Opiant Pharmaceuticals to present at Jefferies Virtual London Healthcare Conference
04:05pm, Wednesday, 10'th Nov 2021
SANTA MONICA, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a company advancing medicines to better treat addictions and drug overdose, today a
Opiant Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021
04:05pm, Thursday, 21'st Oct 2021
SANTA MONICA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug ove
Opiant Pharmaceuticals to Participate in September Investor Conferences
04:05pm, Wednesday, 25'th Aug 2021
SANTA MONICA, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT) today announced that members of the company's senior management team will participat
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2021 Results - Earnings Call Transcript
04:30pm, Saturday, 07'th Aug 2021
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2021 Results - Earnings Call Transcript
Opiant Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 20'th Jul 2021
SANTA MONICA, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and dru
Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer
08:00am, Monday, 12'th Jul 2021
SANTA MONICA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and dru
Opiant Pharmaceuticals Stock Price Increases Over 40% Pre-Market: Why It Happened
07:39am, Wednesday, 07'th Jul 2021
The stock price of Opiant Pharmaceuticals Inc (NASDAQ: OPNT) increased by over 40% pre-market. This is why it happened.
SANTA MONICA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive top-line results from its confirmatory pharmacokinetic (“
Opiant Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference
04:05pm, Monday, 24'th May 2021
SANTA MONICA, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug over
Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00am PDT
04:05pm, Tuesday, 18'th May 2021
SANTA MONICA, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q1 2021 Results - Earnings Call Transcript
07:23pm, Tuesday, 11'th May 2021
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q1 2021 Results - Earnings Call Transcript
Opiant Pharmaceuticals: Q1 Earnings Insights
04:47pm, Tuesday, 11'th May 2021
Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 65.00% over the past year to ($0.66),
